Tags

Type your tag names separated by a space and hit enter

Progestins and breast cancer: an epidemiologic review.
Fertil Steril. 1992 Mar; 57(3):473-91.FS

Abstract

OBJECTIVE

To provide a worldwide review of all studies that have examined the relationship between progestins, as contained in both contraceptive and postmenopausal replacement therapies, and breast cancer risk. An overview of utilization patterns for progestins, as well as a review of possible biological mechanisms for progestins' action on breast tissue, are also presented.

DATA IDENTIFICATION

All major epidemiologic studies conducted since 1980 have been identified through MEDLINE searches through the published literature and personal communications with prominent researchers in the area.

STUDY SELECTION

Only studies that specifically examined the effects of progestin use are discussed here; these include investigations of progestins, in combination or singularly, as the main hypothesis or a subgroup analysis.

RESULTS

The majority of studies have examined combination estrogen and progestin products (oral contraceptives), and subgroup analyses of progestins have been impeded by low statistical power and the fact that each progestin possesses different types of pharmacological activity. Only a few studies of long-acting injectable progestins exist, confirming a general lack of specific information on the progesterone-breast cancer relationship. Investigations of the effect on breast cancer of the addition of progestins to postmenopausal replacement therapy have also produced inconsistent results.

CONCLUSIONS

To date, there is no consistent evidence of an association between progestins and breast cancer. There is need for further study, particularly of patients in potentially high-risk groups, including those with (1) extended hormone exposure before age 25 and/or first full term pregnancy and (2) exposure in the postmenopausal period.

Authors+Show Affiliations

Degge Group, Ltd., Arlington, Virginia 22209.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

1740192

Citation

Staffa, J A., et al. "Progestins and Breast Cancer: an Epidemiologic Review." Fertility and Sterility, vol. 57, no. 3, 1992, pp. 473-91.
Staffa JA, Newschaffer CJ, Jones JK, et al. Progestins and breast cancer: an epidemiologic review. Fertil Steril. 1992;57(3):473-91.
Staffa, J. A., Newschaffer, C. J., Jones, J. K., & Miller, V. (1992). Progestins and breast cancer: an epidemiologic review. Fertility and Sterility, 57(3), 473-91.
Staffa JA, et al. Progestins and Breast Cancer: an Epidemiologic Review. Fertil Steril. 1992;57(3):473-91. PubMed PMID: 1740192.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Progestins and breast cancer: an epidemiologic review. AU - Staffa,J A, AU - Newschaffer,C J, AU - Jones,J K, AU - Miller,V, PY - 1992/3/1/pubmed PY - 1992/3/1/medline PY - 1992/3/1/entrez KW - Biology KW - Breast Cancer--etiology KW - Cancer KW - Contraception KW - Contraceptive Agents, Female--pharmacodynamics KW - Contraceptive Agents, Progestin--pharmacodynamics KW - Contraceptive Agents--pharmacodynamics KW - Contraceptive Methods KW - Depo-provera KW - Diseases KW - Endocrine System KW - Epidemiologic Methods KW - Family Planning KW - High Risk Women KW - Hormones KW - Literature Review KW - Medroxyprogesterone Acetate KW - Menopause KW - Neoplasms KW - Obstacles KW - Oral Contraceptives KW - Oral Contraceptives, Combined KW - Organization And Administration KW - Physiology KW - Progestational Hormones KW - Progesterone--pharmacodynamics KW - Progestins, Low-dose--pharmacodynamics KW - Reproduction KW - Research Methodology KW - World SP - 473 EP - 91 JF - Fertility and sterility JO - Fertil Steril VL - 57 IS - 3 N2 - OBJECTIVE: To provide a worldwide review of all studies that have examined the relationship between progestins, as contained in both contraceptive and postmenopausal replacement therapies, and breast cancer risk. An overview of utilization patterns for progestins, as well as a review of possible biological mechanisms for progestins' action on breast tissue, are also presented. DATA IDENTIFICATION: All major epidemiologic studies conducted since 1980 have been identified through MEDLINE searches through the published literature and personal communications with prominent researchers in the area. STUDY SELECTION: Only studies that specifically examined the effects of progestin use are discussed here; these include investigations of progestins, in combination or singularly, as the main hypothesis or a subgroup analysis. RESULTS: The majority of studies have examined combination estrogen and progestin products (oral contraceptives), and subgroup analyses of progestins have been impeded by low statistical power and the fact that each progestin possesses different types of pharmacological activity. Only a few studies of long-acting injectable progestins exist, confirming a general lack of specific information on the progesterone-breast cancer relationship. Investigations of the effect on breast cancer of the addition of progestins to postmenopausal replacement therapy have also produced inconsistent results. CONCLUSIONS: To date, there is no consistent evidence of an association between progestins and breast cancer. There is need for further study, particularly of patients in potentially high-risk groups, including those with (1) extended hormone exposure before age 25 and/or first full term pregnancy and (2) exposure in the postmenopausal period. SN - 0015-0282 UR - https://www.unboundmedicine.com/medline/citation/1740192/Progestins_and_breast_cancer:_an_epidemiologic_review_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(16)54888-2 DB - PRIME DP - Unbound Medicine ER -